When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the ...

According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...

Washington DC-based Vanda was sent a complete response letter (CRL) from the FDA in 2019, rejecting Hetlioz (tasimelteon) for ...

Guaranteed domain ownership: The first to pre-register a specific .med domain will be guaranteed to secure it at launch. Go ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

It is in the shadow of these changes that the 7th Cell Therapy Analytical Development Summit returns to unite the field.

Six digital health technologies (DHTs) that can help with the rehabilitation of people with cardiovascular disease have been ...

Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to tackle one or more of those areas. But what if an agency were to redesign ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...